Research Library

BPC-157 is a synthetic 15-amino-acid fragment based on a partial sequence of a protein isolated from human gastric juice. Published research consists almost entirely of rodent and cell-culture studies examining angiogenesis (VEGF-related vessel growth), nitric-oxide signaling, and healing responses in gastric, intestinal, tendon, ligament, and muscle tissue. No completed controlled human trials have been identified, so human dosing, pharmacokinetics, and adverse-effect data do not exist in the peer-reviewed literature, and BPC-157 has not been evaluated or approved by the FDA for any human use.

Explore primary publications on PubMed →

GHK-Cu is a naturally occurring copper-binding tripeptide whose tissue concentration declines with age, and it is already used as an ingredient in topical cosmetic skincare formulations. Small published human trials of topical GHK-Cu preparations have measured skin-appearance outcomes, while separate laboratory studies have examined collagen and glycosaminoglycan synthesis, gene-expression modulation, and hair-follicle and wound-healing activity in cell and animal systems. These topical/cosmetic findings are distinct from an injectable research-vial formulation, which has not been evaluated or approved by the FDA, and no controlled human safety data exist for that route of administration.

Explore primary publications on PubMed →

NAD+ is a coenzyme central to cellular redox reactions and serves as a substrate for sirtuin and PARP enzymes implicated in DNA repair and mitochondrial function. Preclinical studies have examined age-related decline in cellular NAD+ pools, and early human trials of NAD+ precursor compounds (such as NMN and NR) have reported mostly mild gastrointestinal adverse events with no major safety signals over the relatively short trial durations conducted to date. Direct human trials of injected NAD+ itself, as opposed to oral precursors, remain limited, and long-term safety data are not established for a research-grade vial.

Explore primary publications on PubMed →

MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA, first characterized in a 2015 study showing effects on AMPK signaling, diet-induced obesity, and insulin resistance in mice. Subsequent preclinical work has explored its role in pancreatic islet cell senescence and diabetes-related cellular aging. A registered clinical trial has recently begun recruiting to examine insulin sensitivity in adults with prediabetes and overweight/obesity, but no results or human safety data from that trial have been published as of this writing, and MOTS-c has not been evaluated or approved by the FDA for any human use.

Explore primary publications on PubMed →

Selank is a synthetic heptapeptide analog of tuftsin studied in cell-culture work for effects on GABA-A receptor gene expression and in animal models for effects on BDNF expression and monoamine turnover linked to anxiety-like behavior. It is reported to be registered as a prescription anxiolytic product in Russia, but it has not been evaluated or approved by the FDA in the United States, and independent, peer-reviewed controlled human trial data outside Russian-language sources remain limited, so a reliable adverse-effect profile is not established in the literature reviewed here.

Explore primary publications on PubMed →

SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide that binds cardiolipin on the inner mitochondrial membrane, studied for effects on cristae structure, electron transport chain efficiency, and reactive oxygen species production. It has been evaluated in human clinical trials, including a Phase 2/3 trial and long-term open-label extension in Barth syndrome, a rare genetic disorder of mitochondrial cardiolipin metabolism. Reported adverse events across these trials have included injection-site skin reactions and gastrointestinal symptoms. These trials involved a specific pharmaceutical-grade investigational drug under clinical supervision, not a catalog research vial, and do not establish general anti-aging or health benefits for research-grade material.

Explore primary publications on PubMed →

Adamax is a vendor name used for a marketed research blend described as a structurally modified, longer-acting Semax derivative. No independent peer-reviewed studies, preclinical data, or clinical trials were located under the name “Adamax.” Vendor materials reference unspecified or uncited preclinical work rather than verifiable academic publications, and any proposed mechanism is inferred from the parent compound Semax rather than independently established for this compound itself.

Explore primary publications on PubMed →

ARA-290 (cibinetide) is an 11-amino-acid peptide derived from erythropoietin and engineered to selectively activate the “innate repair receptor” (an EPOR/CD131 complex) without stimulating red blood cell production. It has been evaluated in Phase 2 human clinical trials for sarcoidosis-associated small-nerve-fiber neuropathy, generally reported as well tolerated, though comprehensive long-term human safety data remain limited. These trials involved a specific investigational drug under clinical supervision, not a catalog research vial, and the findings do not establish general health benefits or safety for research-grade material.

Explore primary publications on PubMed →

This blend combines two separately studied peptides: BPC-157, a gastric-juice-derived fragment studied for angiogenesis and nitric-oxide-related tissue healing, and TB-500, a fragment related to thymosin beta-4 studied for actin-regulatory activity, cell migration, and endothelial signaling relevant to wound healing. Both components have been studied primarily in rodent and, in some cases, equine models of tendon, ligament, muscle, and soft-tissue injury; neither has completed controlled human clinical trials, and no human pharmacokinetic or adverse-event data exist in the peer-reviewed literature for either peptide alone or in combination.

Explore primary publications on PubMed →

Cagrilintide is a long-acting, acylated amylin receptor agonist studied for its role in gastric emptying and satiety signaling. It has been evaluated in randomized, placebo-controlled Phase 2 and Phase 3 human trials, both alone and in combination with semaglutide (as “CagriSema”), for body weight and glycemic outcomes. Across these trials, the most commonly reported adverse events have been gastrointestinal — nausea, vomiting, and related effects — along with injection-site reactions, and cagrilintide remains unapproved by the FDA. These findings concern a specific investigational drug studied under clinical protocols, not a catalog research vial.

Explore primary publications on PubMed →

Cartalax is a synthetic short peptide bioregulator studied on a limited basis for effects on chondrocyte-related gene expression in early laboratory work. Independent, peer-reviewed research outside the originating research group is sparse, no controlled human trials were identified, and no human safety or adverse-event data exist in the literature reviewed here. Cartalax has not been evaluated or approved by the FDA for any human use, and given how limited the published evidence base is, these preliminary findings should be treated with caution.

Explore primary publications on PubMed →

CJC-1295 No DAC (Modified GRF 1-29) is a stabilized fragment of growth hormone-releasing hormone studied for its ability to stimulate pulsatile growth hormone release from the pituitary. A related long-acting formulation conjugated to a drug affinity complex (CJC-1295 with DAC) was evaluated in a small published human trial in healthy adults, reporting sustained increases in GH and IGF-1 levels with mild injection-site reactions among the noted effects; this DAC-conjugated version has different pharmacokinetics and is not the compound described here. No comparable published human trial data exist specifically for the No-DAC form, and it has not been evaluated or approved by the FDA.

Explore primary publications on PubMed →

This blend combines CJC-1295, a growth hormone-releasing hormone analog, with Ipamorelin, a pentapeptide first characterized as an early growth hormone secretagogue found to be selective for GH release without significantly raising cortisol, prolactin, or ACTH. Preclinical research has examined the combined activation of GHRH and ghrelin/GHS-receptor pathways for additive effects on GH pulse amplitude and downstream IGF-1 signaling. No controlled human clinical trial of this specific two-peptide combination was identified, and comprehensive human safety data for the combination do not exist; neither peptide is FDA-approved for human use.

Explore primary publications on PubMed →

DSIP is a peptide first isolated from rabbit brain in the 1970s. A small double-blind human trial in chronic insomnia patients found intravenous dosing produced only modest, possibly placebo-level changes in objective sleep measures, with the trial's own authors concluding short-term DSIP was “not likely to be of major therapeutic benefit.” Separate rodent studies examined antinociceptive effects, HPA-axis/ACTH modulation, and post-stroke motor recovery, and no adequately powered modern human study has established an adverse-effect profile for DSIP.

Explore primary publications on PubMed →

Epitalone (Epitalon) is a synthetic tetrapeptide modeled on pineal-gland extract, studied almost entirely by a small number of research groups. Cell-culture work has reported increased telomerase activity in fibroblasts, rodent studies have reported extended lifespan and reduced spontaneous tumor incidence, and one small, uncontrolled human study in retinitis pigmentosa patients reported improved retinal findings. This literature has not been independently replicated at scale, and no rigorous human safety or adverse-effect data exist.

Explore primary publications on PubMed →

GLOW combines three separately studied peptides. GHK-Cu has rodent, rabbit, and small human skin data on wound contraction and collagen synthesis; BPC-157 has an extensive animal literature but no completed human trials; TB-500's evidence derives mostly from its parent molecule thymosin beta-4, with direct TB-500 data limited to preclinical work and no human musculoskeletal trials. None of the three components has an established human adverse-effect profile in injectable form, and the three-peptide combination itself has never been studied together.

Explore primary publications on PubMed →

KLOW adds KPV, a tripeptide alpha-MSH fragment studied in mouse colitis and colitis-associated-cancer models for anti-inflammatory NF-κB effects, to the GHK-Cu, BPC-157, and TB-500 components described for GLOW. Each peptide's evidence base is limited to isolated animal or cell-culture work; none has completed a human clinical trial, and the four-peptide combination has never been studied together in any model, so no injectable-route safety data exist for the blend.

Explore primary publications on PubMed →

Human chorionic gonadotropin is an FDA-approved prescription drug with decades of clinical use for ovulation induction and male hypogonadism, acting via the LHCG receptor to stimulate steroidogenesis. Its documented adverse-effect profile, from regulated pharmaceutical use under medical supervision, includes headache, mood changes, injection-site reactions, gynecomastia, fluid retention, and ovarian hyperstimulation syndrome risk. This safety and efficacy history applies to a defined, quality-controlled pharmaceutical product administered at prescribed doses under medical supervision — not to an unregulated research-vial product of unverified purity or concentration.

Explore primary publications on PubMed →

Des(1-3)IGF-1 is a truncated IGF-1 analog studied in rodent and cell-culture research for reduced IGF-binding-protein affinity and increased bioactivity relative to native IGF-1. No human clinical trials of this analog have been identified. IGF-1-receptor agonism generally carries theoretical hypoglycemia and cell-proliferation risks that have not been characterized for this specific compound in humans, and it has not been evaluated or approved by the FDA.

Explore primary publications on PubMed →

IGF-1 LR3 is an engineered, long-acting IGF-1 analog studied in cell culture and rodent models — including catabolic (dexamethasone-treated) rats and vascular smooth-muscle-cell assays — for reduced binding-protein affinity, extended half-life, and increased receptor potency. No human clinical trials have been identified, and IGF-1-receptor agonism's theoretical hypoglycemia and proliferation risks remain uncharacterized for this analog in humans.

Explore primary publications on PubMed →

5-Amino-1MQ is a small-molecule NNMT inhibitor (not a peptide) studied only in mice to date — in diet-induced-obesity models, where it reduced fat mass and altered gut microbiome composition, and in aged-mouse models, where NNMT inhibition tracked with improved exercise-linked muscle function. No human clinical trials or human safety data exist for this compound, and it has not been evaluated or approved by the FDA.

Explore primary publications on PubMed →

KPV is a tripeptide fragment of alpha-MSH studied in cell-based assays for inhibition of TNF-alpha-stimulated NF-κB activation, and in mouse colitis and colitis-associated-cancer models for transporter-mediated anti-inflammatory effects. No human clinical trials of KPV have been identified, its human safety profile is unknown, and it has not been evaluated or approved by the FDA.

Explore primary publications on PubMed →

Kisspeptin-10 has been studied in small, short-duration clinical-research settings in healthy volunteers, where dosing stimulated luteinizing hormone secretion and pulse frequency, and chronic dosing sustained gonadotropin output over multi-day periods under continuous clinical monitoring. Researchers have noted that continuous exposure can desensitize the response, and no kisspeptin-10 product is FDA-approved. These were controlled investigational studies, not evaluations of unregulated research-vial material of unverified purity or sterility.

Explore primary publications on PubMed →

Melanotan 1 is closely related to afamelanotide, an MC1R-selective peptide that underwent human trials and was FDA-approved as Scenesse for erythropoietic protoporphyria. Those trials documented adverse effects including nausea, headache, fatigue, and skin/mole darkening requiring dermatologic monitoring, and afamelanotide is dispensed only as a controlled-release implant under medical supervision, not as a self-administered injectable. No equivalent trial of injectable “Melanotan 1” material has been conducted, so research vials are not the approved, quality-controlled product that was studied.

Explore primary publications on PubMed →

Melanotan 2 is a non-selective MC1/MC3/MC4/MC5 agonist studied in animal models for melanogenesis, MC4R-linked arousal responses, and appetite pathways; this work informed the later MC4R-selective analog bremelanotide (Vyleesi), whose FDA trials documented nausea, flushing, headache, and blood-pressure increases. Melanotan 2 itself has never completed an FDA-reviewed human trial, and multiple national regulators have issued public warnings after reports of nausea, hyperpigmentation, and new or changing moles in unsupervised users, with melanoma-risk reviews remaining inconclusive.

Explore primary publications on PubMed →

NAD+ is a coenzyme required for mitochondrial ATP production, sirtuin activity, and PARP-mediated DNA repair, with tissue levels known to decline with age. Animal studies restoring NAD+ levels have reported improvements in markers of mitochondrial function and metabolic health, and early human trials of oral NAD+ precursors have shown dose-dependent increases in blood NAD+ levels with mostly mild gastrointestinal side effects. Human data on direct, high-concentration NAD+ administration remain limited, and these findings come from precursor compounds and animal models, not a specific “Super NAD+” formulation.

Explore primary publications on PubMed →

Bremelanotide (PT-141) is a melanocortin MC3/MC4 receptor agonist studied in Phase III human trials, leading to FDA approval (as Vyleesi) for hypoactive sexual desire disorder in premenopausal women. Clinical trials reported nausea, flushing, headache, and transient blood-pressure increases as common adverse effects, and an earlier intranasal formulation was discontinued over blood-pressure safety concerns. This evidence pertains to a regulated pharmaceutical administered under medical supervision, not unregulated research-vial material.

Explore primary publications on PubMed →

Retatrutide activates GIP, GLP-1, and glucagon receptors. A randomized phase 2 obesity trial found substantial weight reduction, with gastrointestinal adverse effects and increases in heart rate. These findings concern a controlled investigational medicine, not catalog research vials. Retatrutide remains unapproved by the FDA; the trial does not establish general longevity, muscle-building, or performance benefits, and longer-term benefits and risks require continued evaluation.

Explore primary publications on PubMed →

Semax is a synthetic ACTH(4-10) analog studied mainly in Russian preclinical and clinical research. Rodent studies report increased BDNF protein/mRNA expression and trkB receptor phosphorylation in the hippocampus after intranasal dosing, alongside improved performance on conditioned learning and memory tasks. It has regulatory approval and clinical use in Russia for certain neurological and cerebrovascular indications but is not FDA-approved and lacks large-scale Western trial data, so these findings do not establish safety or benefit for a research-grade vial in the United States.

Explore primary publications on PubMed →

SLU-PP-332 is a synthetic pan-agonist of estrogen-related receptors (ERR-alpha/beta/gamma) studied only in laboratory and animal settings. Mouse studies report increased fatigue-resistant muscle fiber composition and improved treadmill endurance, alongside gene-expression changes consistent with exercise-like metabolic activation. Related work has examined effects in metabolic syndrome models, but no human clinical trials or safety data currently exist for this early-stage tool compound.

Explore primary publications on PubMed →

SNAP-8 (acetyl octapeptide-3) is a synthetic peptide studied in vitro for competing with SNAP-25 within the SNARE complex, a mechanism linked to reduced neurotransmitter release in cultured neuronal models. Cosmetic-chemistry research has examined skin-penetration characteristics using 3D epidermal models and correlation with reduced muscle micro-contraction frequency. No clinical trials, systemic safety studies, or human injection data were identified, so these findings are limited to in vitro and topical cosmetic-ingredient research.

Explore primary publications on PubMed →

Tesamorelin is a GHRH analog studied in randomized controlled trials and approved by the FDA (as Egrifta) for reducing visceral adipose tissue in HIV-associated lipodystrophy. Trials and meta-analyses report effects on hepatic fat content, IGF-1 levels, and body composition, alongside documented adverse effects including injection-site reactions, joint and muscle pain, and increases in blood glucose. It is not approved or studied for general weight loss outside this indication, and this evidence pertains to a regulated pharmaceutical administered under medical supervision, not unregulated research-vial material.

Explore primary publications on PubMed →

Tirzepatide is a dual GIP/GLP-1 receptor agonist studied across large Phase 3 trial programs and approved by the FDA (as Mounjaro/Zepbound) for type 2 diabetes and chronic weight management. Trials report significant HbA1c and body-weight reductions, alongside well-documented gastrointestinal adverse effects (nausea, vomiting, diarrhea) and rare but serious risks including pancreatitis and gallbladder disease. This evidence pertains to a regulated, prescription-only pharmaceutical administered under medical supervision, not unregulated research-vial material.

Explore primary publications on PubMed →

TB-500 is marketed as a synthetic fragment or analog of thymosin beta-4, an actin-binding protein studied across cell, animal, and limited human research concentrated mostly in eye and wound-care applications rather than musculoskeletal use. Animal models, including rodent bone, tendon, and skin-flap studies, have examined effects on angiogenesis, cell migration, inflammation, and collagen remodeling. The evidence base is weighted toward in vitro and mixed-design studies, with limited controlled human data specific to TB-500 itself, and it has not been evaluated or approved by the FDA.

Explore primary publications on PubMed →

Thymosin Alpha-1 is a synthetic thymic peptide studied for immunomodulatory effects, including T-cell maturation and cytokine signaling, and is approved as a prescription immune-supportive therapy in a number of countries outside the U.S., though not FDA-approved. Preclinical cancer models report reduced tumor volume and increased immune-cell infiltration, and engineered long-acting fusion versions show extended half-life and immune-organ recovery in animal studies. Clinical use elsewhere has generally been associated with mild adverse effects such as injection-site reactions.

Explore primary publications on PubMed →

Bacteriostatic Water is a sterile diluent containing a small amount of benzyl alcohol as a preservative, used in laboratory settings to reconstitute lyophilized peptide powders into a liquid solution for handling and measurement. It is a preparation solvent, not a peptide or research compound in its own right, so no independent health-benefit research applies to it.

Explore primary publications on PubMed →

Acetic Water is a dilute acetic acid solution used in laboratory settings to reconstitute peptides that are less chemically stable in bacteriostatic water, most often melanocortin-family compounds that hold up better at a lower pH. It is a preparation solvent, not a peptide or research compound in its own right, so no independent health-benefit research applies to it.

Explore primary publications on PubMed →